LEAP2A

LEAP2A
Name	LEAP2A
Organism	Homo sapiens

LEAP2A LEAP2A is a peptide-encoding gene product implicated in endocrine signaling and metabolic homeostasis. It has been investigated in contexts including appetite regulation, hormone interaction, and pathophysiological states such as obesity and cachexia. Studies span molecular biology, clinical endocrinology, and comparative genomics involving diverse model organisms.

Introduction

LEAP2A was characterized through transcriptomic screens alongside genes identified in projects such as the Human Genome Project, ENCODE project, FANTOM Consortium, GTEx project, and collaborative initiatives between institutions like National Institutes of Health and Wellcome Trust. Initial protein annotation drew on resources from UniProt, RefSeq, and sequence data curated by NCBI. Investigations into LEAP2A intersect with research on peptides studied by laboratories at Harvard University, Stanford University, Max Planck Society, Cold Spring Harbor Laboratory, and clinical centers including Mayo Clinic and Johns Hopkins Hospital.

Gene and Protein Structure

The LEAP2A locus was mapped with techniques developed in laboratories familiar to researchers from Broad Institute, Sanger Institute, and European Molecular Biology Laboratory. Genomic characterization used methods standardized by consortia such as 1000 Genomes Project and tools from Ensembl and UCSC Genome Browser. Protein domain prediction leveraged algorithms from groups at MIT and Carnegie Mellon University and compared against families cataloged by Pfam and InterPro. Structural models were informed by principles from X-ray crystallography studies at Argonne National Laboratory and by computational pipelines influenced by work from DeepMind and Rosetta Commons.

Expression and Regulation

Expression profiling of LEAP2A employed platforms developed by Affymetrix, Illumina, and single-cell approaches advanced by teams at Broad Institute and Stanford University. Regulatory studies referenced transcription factor atlases generated at ENCODE project and signal transduction research from groups at Salk Institute and Cold Spring Harbor Laboratory. Hormonal modulation experiments connected LEAP2A expression to pathways investigated by researchers at Dana-Farber Cancer Institute, Mount Sinai Hospital, and endocrine units in universities such as University of Cambridge and University of Oxford.

Biological Function and Mechanism

Functional work on LEAP2A built on receptor pharmacology frameworks developed at Novartis, Pfizer, and academic centers including Yale University and University of California, San Francisco. Mechanistic insight referenced ligand–receptor paradigms akin to those studied for ghrelin, leptin, insulin, and peptide hormones explored by teams at Imperial College London and University of Pennsylvania. Cellular assays used protocols from laboratories at ETH Zurich and University of Tokyo to dissect signaling cascades and downstream effectors implicated in energy balance and metabolic regulation.

Clinical Significance and Disease Associations

Clinical correlations involving LEAP2A have been examined in cohorts assembled at institutions such as Cleveland Clinic, Karolinska Institutet, Massachusetts General Hospital, and networks including European Society of Endocrinology and Endocrine Society. Studies related LEAP2A levels to conditions investigated in trials registered through ClinicalTrials.gov and patient registries maintained by World Health Organization collaborations. Associations were compared with biomarkers used in diagnostics at Mayo Clinic Laboratories and therapeutic targets explored by pharmaceutical companies like AstraZeneca and GlaxoSmithKline.

Evolutionary Conservation and Comparative Genomics

Comparative analyses referenced sequences from repositories curated by GenBank, Ensembl, and the UCSC Genome Browser and drew phylogenetic context from projects such as the Tree of Life Web Project and datasets produced by Zoonomia Project. Evolutionary rates and conserved motifs were evaluated against orthologs reported in studies from Max Planck Institute for Evolutionary Anthropology and large-scale comparative initiatives involving organisms studied at Smithsonian Institution and Natural History Museum, London.

Research Tools and Experimental Methods

Experimental approaches for studying LEAP2A include assays developed using reagents from Thermo Fisher Scientific, vectors and genome editing methods popularized by Addgene and CRISPR tools conceptualized in reports from Broad Institute and University of California, Berkeley. Proteomics and mass spectrometry workflows were implemented using instruments by Thermo Fisher Scientific and protocols influenced by groups at European Molecular Biology Laboratory. Imaging and histology follow standards set by core facilities at institutions like Johns Hopkins University and University of California, Los Angeles.

Category:Human proteins